Welcome to Paid Research Studies




  • Conditions:   Epstein-Barr Virus Infections;   Immunodeficiency
    Intervention:  
    Sponsor:   Children's Hospital of Fudan University
    Recruiting

  • Conditions:   Epstein-Barr Virus Infections;   Lymphoma;   Lymphoproliferative Disorder;   Disorders, Lymphoproliferative
    Intervention:   Drug: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD);   Stem Cell Transplant Complications;   Lymphoproliferative Disorders
    Intervention:   Biological: tabelecleucel
    Sponsor:   Atara Biotherapeutics
    Recruiting

  • Conditions:   Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD);   Solid Organ Transplant Complications;   Lymphoproliferative Disorders
    Intervention:   Biological: tabelecleucel
    Sponsor:   Atara Biotherapeutics
    Recruiting

  • Conditions:   Nasopharyngeal Carcinoma;   Nasopharyngeal Neoplasms;   Epstein-Barr Virus Infections;   Epstein-Barr Viraemia;   Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
    Interventions:   Biological: tabelecleucel;   Biological: pembrolizumab
    Sponsors:   Atara Biotherapeutics;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Epstein-Barr Virus Infections;   Primary Immune Deficiency Disorder
    Intervention:   Drug: cytotoxic t-lymphocytes
    Sponsors:   New York Medical College;   Children's Hospital of Philadelphia;   Medical College of Wisconsin
    Recruiting

  • Conditions:   Epstein-Barr Virus Infections;   Post-Transplant Lymphoproliferative Disorder;   Lymphoma
    Interventions:   Biological: Group A;   Biological: Group B
    Sponsor:   Dr. Jean-Sebastien Delisle, MD, PhD
    Recruiting

  • Conditions:   Epstein-Barr Virus Associated Lymphoma;   Lymphoproliferative Disorders
    Interventions:   Drug: VRx-3996;   Drug: Valganciclovir
    Sponsor:   Viracta Therapeutics, Inc.
    Recruiting

  • Conditions:   Epstein-Barr Virus (EBV) Infections;   Lymphoproliferative Disorders;   EBV+ Associated Lymphoma;   EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD);   Epstein-Barr Viremia;   Lymphoma, AIDS-related;   Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID);   Leiomyosarcoma (LMS);   Nasopharyngeal Carcinoma (NPC);   Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID);   Solid Organ Transplant Complications;   Stem Cell Transplant Complications
    Intervention:   Biological: tabelecleucel
    Sponsor:   Atara Biotherapeutics
    Available

  • Conditions:   Epstein-Barr Virus Infections;   Adenovirus;   Cytomegalovirus Infections
    Intervention:   Biological: Cytotoxic T Lymphocytes
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Conditions:   Acute Lymphocytic Leukemia;   Lymphoma
    Interventions:   Biological: Biological/Genetically Modified T cells;   Drug: Cyclophosphamide-based chemotherapy
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Nasopharyngeal Carcinoma
    Intervention:   Diagnostic Test: Plasma EBV DNA
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Condition:   Peri-Implantitis
    Interventions:   Procedure: peri implantitis sanitation surgery;   Other: Care
    Sponsor:   Centre Hospitalier Universitaire de Nice
    Recruiting

  • Condition:   Nasopharyngeal Carcinoma
    Interventions:   Drug: sintilimab;   Drug: Capecitabine
    Sponsors:   Sun Yat-sen University;   National Cancer Centre, Singapore;   Wuzhou Red Cross Hospital
    Not yet recruiting

  • Conditions:   COPD;   EBV
    Interventions:   Drug: Valaciclovir;   Drug: Placebo capsules (containing Avicel blend)
    Sponsors:   Belfast Health and Social Care Trust;   Northern Ireland Clinical Trials Unit;   Queen's University, Belfast
    Recruiting

  • Conditions:   NonHodgkin Lymphoma;   Lymphoproliferative Disorders;   EBV Related Lymphoma;   EBV-Related PTLD;   Hodgkin Lymphoma;   EBV Related Non-Hodgkin's Lymphoma;   EBV Related Hodgkin's Lymphoma
    Interventions:   Biological: EBVST Cells;   Biological: Nivolumab
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Epstein-Barr Viraemia;   Hematologic Diseases;   Allogeneic Disease
    Intervention:   Biological: biological collection
    Sponsors:   Assistance Publique - Hôpitaux de Paris;   Institut National de la Santé Et de la Recherche Médicale, France
    Recruiting

  • Conditions:   Epstein-Barr Virus Infection;   Stage II Nasopharyngeal Carcinoma;   Stage III Nasopharyngeal Carcinoma;   Stage IVA Nasopharyngeal Carcinoma;   Stage IVB Nasopharyngeal Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   EBV Infection
    Interventions:   Drug: PD1 antibody;   Drug: lenalidomide
    Sponsor:   Beijing Friendship Hospital
    Recruiting

  • Conditions:   Transplantation Infection;   Epstein-Barr Virus Infections;   Cytomegalovirus Infections
    Interventions:   Drug: Valacyclovir;   Drug: Valganciclovir
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Recruiting

  • Conditions:   Nasopharyngeal Carcinoma;   Nasopharyngeal Cancer
    Intervention:   Drug: VK-2019
    Sponsor:   Cullinan Apollo Corporation
    Recruiting

  • Condition:   Nasopharyngeal Cancinoma (NPC)
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Nasopharyngeal Carcinoma
    Interventions:   Biological: autologous EBV specific Cytotoxic T cells;   Drug: combination IV gemcitabine and IV carboplatin (AUC2)
    Sponsor:   Tessa Therapeutics
    Recruiting

  • Condition:   Hemophagocytic Lymphohistiocytosis
    Interventions:   Drug: Etoposide;   Drug: Dexamethasone;   Drug: IVIG
    Sponsor:   Beijing Friendship Hospital
    Not yet recruiting

  • Conditions:   Transplant; Failure, Kidney;   EBV
    Interventions:   Drug: belatacept;   Drug: Tacrolimus;   Drug: MPA
    Sponsors:   Lorenzo Gallon;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
    Interventions:   Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Severe Chronic Active EBV Infection Syndrome (SCAEBV);   Leiomyosarcoma
    Interventions:   Drug: LMP1/2 CTLs (Group A);   Drug: LMP1/2 CTLs (Group B)
    Sponsor:   Catherine Bollard
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Cytomegalovirus Infections;   Adenovirus Infection;   EBV Infection
    Intervention:   Biological: Virus Specific T-cell (VST) infusion
    Sponsor:   Michael Pulsipher, MD
    Recruiting

  • Condition:   Viral Infection
    Intervention:   Biological: HLA-matched VSTs
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Not yet recruiting

  • Conditions:   Locally Recurrent Cancer;   Metastatic Nasopharyngeal Cancer
    Interventions:   Drug: pembrolizumab;   Drug: bevacizumab
    Sponsors:   National University Hospital, Singapore;   Merck Sharp & Dohme Corp.
    Not yet recruiting

  • Conditions:   Pathogen Infection;   EBV Infection;   CMV Infection;   Adenovirus Infection;   BKV Infection;   Fungus Infection;   Tuberculosis
    Intervention:   Biological: pathogen-specific CTLs
    Sponsor:   Shenzhen Geno-Immune Medical Institute
    Recruiting

  • Conditions:   Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Biological: Interferon;   Drug: Rituxan and EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Acute Lymphoblastic Leukemia;   Mixed Lineage Leukemia;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   Juvenile Myelomonocytic Leukemia
    Intervention:   Device: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Diffuse Large B-cell Lymphoma
    Intervention:   Biological: Tisagenlecleucel
    Sponsor:   Novartis Pharmaceuticals
    Not yet recruiting

  • Condition:   Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: CD19-CD22 CAR-T cells
    Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Juventas Cell Therapy Ltd.
    Not yet recruiting

  • Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5 Percent or More of Peripheral Blood White Cells;   CD22 Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B Lymphoblastic Lymphoma
    Interventions:   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Drug: Cyclophosphamide;   Biological: Inotuzumab Ozogamicin;   Biological: Rituximab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation;   B-Cell Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Lymphoblastic Leukemia, Adult
    Intervention:   Drug: Blinatumomab in combination with donor lymphocyte infusion
    Sponsors:   Ludwig-Maximilians - University of Munich;   Amgen
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Drug: Inotuzumab ozogamicin;   Drug: Prednisone Pill;   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Pegaspargase
    Sponsors:   University of Virginia;   Pfizer;   Vanderbilt University;   University of Wisconsin, Madison;   Virginia Commonwealth University
    Not yet recruiting

  • Condition:   B-Cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: CTL019
    Sponsors:   Novartis Pharmaceuticals;   Children's Oncology Group
    Recruiting

  • Conditions:   Diffuse Large B Lymphoma (DLBCL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL);   Marginal Zone Lymphoma (MZL);   T-cell Lymphoma (T-NHL);   Hodgkin's Lymphoma (HL);   Burkitt Lymphoma (BL))
    Intervention:   Other: Real-life epidemiological platform of lymphoma in France
    Sponsors:   Hospices Civils de Lyon;   The Lymphoma Academic Research Organisation
    Recruiting

  • Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   B Cell Lymphoma;   B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: Anti-CD19 CAR-T Cells Injection
    Sponsors:   Yan'an Affiliated Hospital of Kunming Medical University;   KAEDI
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: GC022
    Sponsors:   Hebei Yanda Ludaopei Hospital;   Gracell Biotechnology Ltd.
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: GC007F
    Sponsors:   Hebei Yanda Ludaopei Hospital;   Gracell Biotechnology Ltd.
    Recruiting

  • Conditions:   Lymphoma;   Leukemia
    Intervention:   Drug: CPI-613
    Sponsors:   Memorial Sloan Kettering Cancer Center;   City of Hope Medical Center;   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   George Washington University
    Recruiting

  • Condition:   Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI
    Intervention:   Biological: Specificity CD38 CAR-T Cells
    Sponsor:   Chinese PLA General Hospital
    Recruiting

  • Conditions:   B-Cell Acute Lymphoblastic Leukaemia;   ALL, Adult;   B-ALL
    Interventions:   Drug: Blinatumomab;   Other: Haplo-Mismatched Cell Therapy (HMCT)
    Sponsors:   Cedars-Sinai Medical Center;   Amgen
    Not yet recruiting

  • Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   CD22 Positive;   Philadelphia Chromosome Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Intervention:   Biological: ADCT-602
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   ADC Therapeutics S.A.
    Recruiting

  • Conditions:   Burkitt Lymphoma;   Retinoblastoma
    Intervention:   Other: mNavigator
    Sponsors:   Duke University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: PBCAR0191;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Precision BioSciences, Inc.
    Recruiting

  • Condition:   Leukemia, B-cell
    Intervention:   Biological: CART-19/22
    Sponsors:   Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd;   The First Affiliated Hospital of Soochow University
    Recruiting

  • Condition:   Acute Lymphoid Leukemia
    Intervention:   Drug: Inotuzumab Ozogamicin (IO)
    Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
    Not yet recruiting

  • Condition:   Leukemia, B-Cell
    Intervention:   Biological: CD19-targeted CART cells
    Sponsor:   jiuwei cui
    Not yet recruiting

  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis;   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
    Interventions:   Drug: ABL001;   Drug: Dasatinib;   Drug: Prednisone
    Sponsors:   Marlise R. Luskin;   Novartis
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Diagnostic Test: NGS-MRD;   Drug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
    Sponsor:   Children's Hospital Los Angeles
    Recruiting

  • Conditions:   Infectious Mononucleosis;   Splenomegaly
    Intervention:   Device: Point-of-care ultrasound
    Sponsor:   Jewish General Hospital
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia;   T Acute Lymphoblastic Leukemia
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax;   Drug: Vincristine Liposomal
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Palbociclib;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Pfizer
    Recruiting

  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Acute Lymphocytic Leukemia, Pediatric
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Tocilizumab
    Sponsor:   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia;   B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: AUTO3 (CD19/22 CAR T cells
    Sponsor:   Autolus Limited
    Recruiting

  • Conditions:   Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood;   Refractory B-cell Acute Lymphoblastic Leukemia, Childhood;   Relapsed/Refractory B-cell Lymphoma, Childhood
    Intervention:   Biological: BinD19
    Sponsors:   Shenzhen BinDeBio Ltd.;   Children's Hospital of Fudan University
    Recruiting

  • Conditions:   Lymphoma;   Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Ibrutinib;   Drug: Prednisone;   Drug: Obinutuzumab;   Drug: Revlimid (lenalidomide)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-Cell Acute Lymphoblastic Leukemia, Adult
    Interventions:   Drug: blinatumomab;   Drug: pembrolizumab
    Sponsors:   Matthew Wieduwilt, M.D., Ph.D.;   Merck Sharp & Dohme Corp.;   Amgen
    Recruiting

  • Conditions:   Burkitt Leukemia;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Burkitt Leukemia;   Recurrent Burkitt Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Acute Lymphoblastic Leukemia;   Refractory Burkitt Leukemia;   Refractory Burkitt Lymphoma;   Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Lymphoblastic Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Ofatumumab;   Biological: Pegfilgrastim;   Biological: Rituximab;   Drug: Vincristine Sulfate Liposome
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-cell Non Hodgkin Lymphoma;   Pre B-Cell Acute Lymphoblastic Leukaemia
    Interventions:   Drug: Blinatumomab;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Amgen
    Recruiting

  • Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Nivolumab;   Drug: Varlilumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Intervention:  
    Sponsor:   Curewize Health Ltd.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide
    Sponsor:   University of Arizona
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplant Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: UCART19
    Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Burkitt Lymphoma
    Interventions:   Procedure: Leukapheresis;   Drug: Lymphodepletion with fludarabine;   Drug: Lymphodepletion with cyclophosphamide;   Biological: CD19 CAR T-cells
    Sponsor:   University College, London
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: UCART19
    Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   B-cell Acute Lymphoblastic Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Chronic Myeloid Leukemia, Blast Crisis
    Intervention:   Biological: XmAb14045
    Sponsors:   Xencor, Inc.;   Chiltern International Inc.
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
    Intervention:  
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Recruiting

  • Conditions:   CD19 Positive;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Mediastinal Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Blinatumomab;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Primary Mediastinal B-cell Lymphoma;   CD20+ Lymphoblastic Lymphoma;   Follicular Lymphoma, Grade III
    Interventions:   Drug: Obinutuzumab;   Drug: Liposomal ARA-C;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
    Sponsors:   New York Medical College;   Roswell Park Cancer Institute
    Recruiting

  • Conditions:   AIDS-Related Burkitt Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Burkitt Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Burkitt Lymphoma;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Ofatumumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia in Relapse;   Burkitt's Lymphoma Stage III;   Burkitt's Lymphoma Stage IV;   Type 3 Diffuse Large B-Cell Lymphoma
    Interventions:   Behavioral: Individualized Yoga Intervention Group;   Other: iPad Activity Control Group
    Sponsor:   The Hospital for Sick Children
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
    Sponsor:   New York Medical College
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Lymphoblastic Lymphoma;   Diffuse Large B-cell Lymphoma;   Burkitt Lymphoma/Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Mitoxantrone
    Sponsor:   New York Medical College
    Recruiting

  • Conditions:   Adult Solid Tumor;   Diffuse Large B Cell Lymphoma;   Burkitt Lymphoma
    Intervention:   Drug: AZD3965
    Sponsor:   Cancer Research UK
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Viral Infection;   Viral Reactivation;   Infection in an Immunocompromised Host
    Intervention:   Biological: Viral Specific CTL Infusion
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma (DLBCL);   Primary Mediastinal Large B-cell Lymphoma;   Burkitt Lymphoma;   Anaplastic Large-Cell Lymphoma;   Gray Zone Lymphoma
    Interventions:   Drug: EPOCH;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Stem Cell Transplant;   Viral Infection;   Viral Reactivation
    Intervention:   Biological: Viral specific CTL Infusion
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Hoxworth Blood Center
    Recruiting

  • Conditions:   Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Relapsing Remitting Multiple Sclerosis
    Intervention:   Biological: ATA188
    Sponsor:   Atara Biotherapeutics
    Recruiting